Rubicon Research Limited vs Cohance Lifesciences Limited
An objective side-by-side of RUBICON and COHANCE, both in Pharmaceuticals: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: RUBICON Jun 2026 · COHANCE Jun 2026
At a glance
- Rubicon Research Limited is the larger company by market value, about 1.6 times the size of Cohance Lifesciences Limited.
- On trailing earnings, Rubicon Research Limited trades at the lower P/E (135.3 against 182.3).
| Metric | Rubicon Research RUBICON |
Cohance Lifesciences COHANCE |
|---|---|---|
| Size and price | ||
| Market cap | ₹28,604 Cr | ₹17,617 Cr |
| Share price | ₹1,733 | ₹460.45 |
| Valuation | ||
| P/E | 135.29 | 182.33 |
| Profitability | ||
| Operating margin | 23.3% | 15.9% |
| Sales (TTM) | ₹1,422 Cr | ₹2,072 Cr |
| Net profit (TTM) | ₹211 Cr | ₹97 Cr |
| Growth | ||
| Latest quarter sales YoY | — | -23.1% |
| Latest quarter profit YoY | — | -197.4% |
| Financial strength | ||
| Interest cover | — | 6.85 |
| Ownership | ||
| Promoter holding | 59.8% | — |
| Promoter change (4 qtrs) | +0.00 pp | — |
| Price performance | ||
| Return 1M | -1.59% | -3.18% |
| Return 3M | +25.86% | +13.62% |
| Return 1Y | — | -53.27% |
| Return YTD | +154.51% | -12.89% |
| Technical condition | ||
| Technical score | 43 | 62 |
| RS rating (1-99) | 96.00 | 56.00 |
| % vs 200-DMA | +60.52% | +9.42% |
| RSI (14) | 48.59 | 56.79 |
| % from 52-week high | -8.76% | -53.77% |
